H.C. Wainwright Reiterates a Buy Rating on Eyenovia (EYEN)
H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Eyenovia (EYEN) today and set a price target of $6.00. The company’s shares closed last Thursday at $3.49.
According to TipRanks.com, Chen is a 4-star analyst with an average return of 9.5% and a 37.3% success rate. Chen covers the Healthcare sector, focusing on stocks such as Interpace Diagnostics Group, HTG Molecular Diagnostics, and EyePoint Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Eyenovia with a $7.00 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $6.92 and a one-year low of $1.11. Currently, Eyenovia has an average volume of 1.2M.
Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of EYEN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Eyenovia, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company offers a piezo-print technology to deliver micro-doses of micro-therapeutics for the eyes. Its products include MicroProst, MicroStat, MicroTears, and MicroPine. The company was founded on March 12, 2014 and is headquartered in New York, NY.